Supplementary Figure S1

Fig. S1. Effect of Ageritin on differentiated SH-SY5Y cells. Morphology of cells treated with 1.69 μM (25 μg/mL) and 5.07 μM (75 μg/mL) concentrations of Ageritin at three different incubation times (24, 48 and 72 h). Control is represented by untreated cells. Magnification x 10.
Supplementary Figure S2

**Fig. S2.** Effect of Ageritin on Procaspase-3 protein levels. Cells were incubated with vehicle alone or with 1.7, 3.3 or 6.7 µM of Ageritin for 24 h and total protein extracts were used to detect Procaspase-3 levels through Western blotting. β-Actin was used as an internal loading control. Values are reported as mean ± SD of three experiments performed in triplicate. *p < 0.05, compared to respective control cells.
**Supplementary Figure S3**

**Undifferentiated cells**

**A**

Fig. S3. Cytotoxicity of Ageritin towards SH-SY5Y cells. MTT and SRB tests (bar graphs) were performed to evaluate redox activity inhibition (RAI, %) and cell viability inhibition (CVI, %), respectively. Undifferentiated (A-B) and (RA)-differentiated (C-D) cells were treated with 1.7, 3.3 or 6.7 μM of Ageritin at different incubation times [24 h ( ■ ), 48 h ( ■ ) and 72 h ( ■ )]. Values, reported as percentage vs. untreated control cells, represent the mean ± SD of three experiments performed in triplicate. Data were subjected to statistic Two-way ANOVA Bonferroni post-test to calculate the significance (*, P<0.05; **, P<0.01; ***, P<0.001; ns, P>0.05).